Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Antoni Ribas
University of California Los Angeles, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Kite Pharma, Inc.
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution
Dr. Ribas is on the Scientific Advisory Board and is the PI. He will use NY-ESO-1 TCR that is licensed to Adaptimmune. The intellectual property is not assigned to the UC.
Immuno-Targeted Therapy for Melanoma
Studies of the mechanisms of response and resistance to anti-PD-1 and anti-PD-L1 therapies in biopsies of patients with advanced melanoma and in melanoma murine models will provide useful information to design new combinatorial therapies for this cancer. Combination with BRAF and MEK inhibitors in BRAF mutant melanoma may increase the response rates, and in patients whose tumors do not have a pre-existing immune response to cancer we can genetically engineered with TCR ACT.
Filed on April 19, 2016.
Tell us what you know about Antoni Ribas's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Antoni Ribas filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Antoni Ribas | University of California Los Angeles | Conflict of Interest | Kite Pharma, Inc | >$600,000 |
| Antoni Ribas | University of California Los Angeles | Conflict of Interest | Kite Pharma, Inc. | $400,000 - $449,999 |
| Antoni Ribas | University of California Los Angeles | Conflict of Interest | Kite Pharma, Inc | Value cannot be readily determined |
Other search results for: “Antoni Ribas”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Antoni Ribas | University of California Los Angeles | Financial Disclosure | Merck | |
| Antoni Ribas | University of California Los Angeles | Financial Disclosure | Kite Pharma, Inc. | |
| Antoni Ribas | University of California Los Angeles | Financial Disclosure | Merck | |
| Antoni Ribas | University of California Los Angeles | Financial Disclosure | Merck | |
| Antoni Ribas | University of California Los Angeles | Financial Disclosure | Amgen | |
| Antoni Ribas | University of California Los Angeles | Financial Disclosure | Merck | |
| Antoni Ribas | University of California Los Angeles | Financial Disclosure | Merck | |
| Antoni Ribas | University of California Los Angeles | Financial Disclosure | Merck | |
| Antoni Ribas | University of California Los Angeles | Financial Disclosure | Merck |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.